Cannabis and sport

British Journal of Sports Medicine

Volumn 40, Issue SUPPL. 1, 2006, Pages

  Saugy, M ^a   Avois, L ^a   Saudan, C ^a   Robinson, N ^a   Giroud, C ^a   Mangin, P ^a   Dvorak, J ^b  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^b SCHULTHESS CLINIC   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; RECREATIONAL DRUG;

DOPING; DRUG DETERMINATION; DRUG ELIMINATION; DRUG USE; HUMAN; REVIEW; SPORT; URINALYSIS;

CANNABIS; COMPETITIVE BEHAVIOR; DOPING IN SPORTS; HUMANS; SPORTS; SUBSTANCE-RELATED DISORDERS; URINALYSIS;

EID: 33745841911     PISSN: 03063674     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjsm.2006.027607     Document Type: Review

References (18)

1. European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Annual report on the state of the drugs problems in Europe, 2005 (http://annualreport. emcdda.eu.int).
2. United States Department of Health and Human Services. Substance Abuse and Mental Health Service Administration (SAMHSA). Marijuara use and characteristics of users, 2003 (http://oas.samhsa.gov/Mj.htm).
3. Renaud AM, Cormier Y. Acute effects of marihuana smoking on maximal exercise performance. Med Sci Sports Exerc 1986;18:685-9.
4. Menetrey A, Augsburger M, Favrat B, et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg delta9-THC. J Anal Toxicol 2005;29:327-38.
5. Favrat B, Menetrey A, Augsburger M, et al. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry 2005;5:17.
6. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999;83:637-49.
7. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001;178:101-6.
8. Lorente FO, Peretti-Watel P, Grelot L. Cannabis use to enhance sportive and non-sportive performances among French sport students. Addict Behav 2005;30:1382-91.
9. Arvers P, Choquet M. [Sporting activities and psychoactive substance use. Data abstracted from the French part of the European School Survey on Alcohol and other Drugs (ESPAD 99)]. Ann Med Interne (Paris) 2003;154(Spec No 1):S25-34.
10. Cone EJ, Johnson RE, Darwin WD, et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 1987;11:89-96.
11. Leson G, Pless P, Grotenhermen F, et al. Evaluating the impact of hemp food consumption on workplace drug tests. J Anal Toxicol 2001;25:691-8.
12. ElSohly MA. Practical challenges to positive drug tests for marijuana. Clin Chem 2003;49:1037-8.
13. Canadian Legal Information Institute (CANLII). Consolidated Regulations of Canada. Industrial Hemp Regulations SOR/98-156, 1998 (www.canlii.org/ca/regu/ sor98-156/whde.html).
14. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 1998;22:445-54.
15. Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11 -nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 1996;20:441-52.
16. Fraser AD, Worth D. Urinary excretion profiles of 11 -nor-9-carboxy- delta9-tetrahydrocannibinol and 11 -hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV. Foren Sic Sci Int 2004;143:147-52.
17. Ellis GM Jr, Mann MA, Judson BA, et al. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985;38:572-8.
18. Manno JE, Manno BR, Kemp PM, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9- tetrahydrocannabinol, 11 -hydroxy-delta9-tetrahydrocannabinol, and 11 -nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 2001;25:538-49.